Karen Bernstein, PhD has served as a member of our board of directors since September 2015.
Dr. Bernstein has been writing and publishing on biotechnology since 1987. She holds a Ph.D. in political science from Stanford University and a B.A. in politics and history from Brandeis University, where she served from 2003-14 as a member of the Brandeis University Science Advisory Council. Dr. Bernstein is on the board of trustees of the Keck Graduate Institute of the Applied Life Sciences and is a member of the board of advisors of KGI’s School of Pharmacy. In 2005, the annual gathering of biotechnology chief executive officers at The Biotech Meeting in Laguna Niguel, Calif., inducted Dr. Bernstein into their Hall of Fame, citing her lifetime contribution to the biotech community. In 2007, Dr. Bernstein received a Special Recognition award at the American Liver Foundation’s Salute to Excellence, honoring individuals who have made an outstanding contribution to biotechnology and medical innovation. In 2015, Scientific American named her as one of The WorldVIEW 100 most influential people in biotech today. In 2013, she was named as one of the 100 Women of Influence in Silicon Valley by the Silicon Valley Business Journal.
John M. Leonard has served as a member of our board of directors since July 2015.
John M. Leonard, MD, is the Chief Medical Officer of Intellia Therapeutics, a privately held biotechnology company active in gene therapy with CRISPR/Cas9. He served as the Chief Scientific Officer and Senior Vice President of Research & Development at AbbVie from its inception until retiring from that position at the end of 2013. Before the formation of AbbVie from Abbott Laboratories, Dr. Leonard served as the Senior Vice President of Global Pharmaceutical Research and Development at Abbott, where he was employed in various roles before leading the R and D organization. At Abbott, he led teams that made seminal contributions to HIV and HCV therapeutics including the introduction of Norvir, Kaletra and Viekira. In addition, he led the development of multiple indications of Humira and work in various other therapeutic areas. He has over 30 years of combined experience in medicine, research and management.
Prior to joining Abbott, Dr. Leonard worked at G.H. Besselaar Associates. He has served as a member of various industry groups and is a member of the Board of Directors of both Quintiles and Chimerix. Dr. Leonard received his MD from the Johns Hopkins University School of Medicine and trained in Internal Medicine at Stanford University. He received his research training at the Laboratory of Molecular Microbiology at the National Institute of Allergy and Infectious Diseases at the National Institutes of Medicine. He studied Biochemistry at the University of Wisconsin, where he received a BA.
Robert V. Gunderson, Jr. has served as a member of our board of directors since January 2002.
Mr. Gunderson is a founding partner of the law firm of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, where he has practiced since 1995. Mr. Gunderson currently serves as a director of Theravance Biopharma, Inc., as well as a number of private companies.
Mr. Gunderson previously served on the board of Theravance, Inc. Mr. Gunderson holds a J.D. from the University of Chicago, where he was Executive Editor of The University of Chicago Law Review.
Mr. Gunderson also received an M.B.A. in Finance from The Wharton School, University of Pennsylvania and an M.A. from Stanford University.
Mr. Gunderson’s demonstrated leadership in his field, his understanding of our industry and his knowledge of financial and financing matters contributed to our conclusion that he should serve as a director.
Jeffrey S. Hatfield has served as President, Chief Executive Officer and a member of our board of directors since March 2004.
Prior to joining Vitae Pharmaceuticals, Mr. Hatfield worked at Bristol‑Myers Squibb, a large publicly‑ traded biopharmaceutical company, which he joined in 1985, in a variety of executive positions, including: Senior Vice President of Bristol‑Myers Squibb’s Virology and Immunology Divisions from 2000 to 2004; President and General Manager, Canada from 1997 to 2000; and Vice President, U.S. Managed Health Care from 1996 to 1997.
In 2014, Mr. Hatfield became a director of Ambit Biosciences, a biopharmaceutical company.
Mr. Hatfield received a Masters in Business Administration from The Wharton School, University of Pennsylvania and received a bachelor’s degree in Pharmacy from Purdue University.
Our board of directors believes that Mr. Hatfield’s position as our Chief Executive Officer, his extensive experience in general management and his experience in the biopharmaceutical industry qualify him to serve as a member of our board of directors.
Donald Hayden, Jr. has served as a member of our board of directors since 2006 and the Chairman of the board of directors since 2006.
Mr. Hayden previously served as the Executive Chairman of Transave, a biotechnology company, from 2006 until 2010, when Transave was acquired by Insmed, a biotechnology company. From 1981 to 2006, Mr. Hayden was an executive with Bristol‑Myers Squibb Company, where he served in key executive roles including President of Global Pharmaceuticals; Executive Vice President and President, Americas; Executive Vice President of the Health Care Group; President of Oncology and Immunology; and Senior Vice President of Worldwide Franchise Management and Business Development.
Mr. Hayden currently serves as lead independent director of Amicus Therapeutics Inc., a biopharmaceutical company, and as non‑Executive Chairman of the board of directors of Insmed. Mr. Hayden is also a director of Otsuka America Pharmaceuticals, Inc., the U.S. subsidiary of Otsuka Pharmaceutical Company, Limited, a manufacturer of pharmaceuticals and nutraceutical products.
Mr. Hayden also serves on the boards of directors for four privately‑held companies: Alvine Pharmaceuticals; Nora Therapeutics; ReGenX Biosciences; and Dimension Therapeutics. Mr. Hayden is also a senior advisor to Prospect Venture Partners, a venture capital firm.
Mr. Hayden holds a Bachelor of Arts degree in general studies from Harvard University and a Masters of Business Administration degree from Indiana University.
Mr. Hayden’s qualifications to sit on our board include his extensive leadership, executive, managerial and business experience with life sciences companies, including experience in the formation, development and business strategy of multiple start‑up companies in the life sciences sector.
Dan Junius has served as a member of our board of directors since 2016.
Mr. Junius has been a director of ImmunoGen, Inc. since July 2008 and a director of GlycoMimetics, Inc. since March 2016. He was previously President and Chief Executive Officer of ImmunoGen from 2009 until his retirement in May 2016, President and Chief Operating Officer and Acting Chief Financial Officer of from July 2008 to December 2008, Executive Vice President and Chief Financial Officer from 2006 to July 2008 and Senior Vice President and Chief Financial Officer from 2005 to 2006. Before joining ImmunoGen, Mr. Junius was Executive Vice President and Chief Financial Officer of New England Business Service, Inc. from 2002 until its acquisition by Deluxe Corporation in 2004 and Senior Vice President and Chief Financial Officer of New England Business Services from 1998 to 2002. Before joining New England Business Services, Mr. Junius was Vice President and Chief Financial Officer of Nashua Corporation from 1996 to 1998. Mr. Junius joined Nashua Corporation in 1984 and held various financial management positions of increasing responsibility before becoming Chief Financial Officer of Nashua Corporation in 1996. Mr. Junius holds an undergraduate degree in Political Science from Boston College and a Masters in Management from Northwestern University’s Kellogg School of Management.
Charles A. Rowland, Jr. has served as a member of our board of directors since September 2014.
Most recently, Mr. Roland was Vice President and Chief Financial Officer of ViroPharma Incorporated, an international biopharmaceutical company, until it was acquired by Shire plc in January 2014. He also served as Senior Vice President of Finance, with responsibilities for leading the treasury, tax, investor relations and business planning groups. Prior to joining ViroPharma, from 2006 to 2008, Mr. Rowland served as the Executive Vice President and Chief Financial Officer, as well as the interim Co-Chief Executive Officer, for Endo Pharmaceuticals Inc., a specialty pharmaceutical company with a primary focus in pain management. At Endo, Mr. Rowland drove the strategic planning process, including the design and implementation of the company’s mid and long-term strategy. From 2004 to 2006, Mr. Rowland was the Senior Vice President and Chief Financial Officer of Biovail Corporation, an international pharmaceutical company, where he directed all financial activities for the company including tax, treasury, accounting, financial analysis, investor relations as well as all aspects of information technology. Mr. Rowland previously held positions of increasing responsibility at Breakaway Technologies, Inc., Pharmacia Corporation, Novartis AG and Bristol-Myers Squibb Co. Mr. Rowland’s more than 30 years of industry experience in financial management and strategic business operations qualify him to serve on our board of directors.
Gino Santini has served as a member of our board of directors since September 2014.
From 1983 until his retirement in December 2010, Mr. Santini held a variety of commercial and operational roles at Eli Lilly and Company, a public pharmaceutical company. From April 2007 to December 2010, Mr. Santini served as Senior Vice President, Corporate Strategy and Business Development at Eli Lilly, where he led corporate strategy and long-range planning, mergers and acquisitions, new product licensing and the expansion of Lilly Ventures in the United States and China. During his tenure at Eli Lilly, Mr. Santini held various leadership positions of increasing responsibility, including manager of various international regions, Senior Vice President of Corporate Strategy and Policy from 2004 to 2007, President of U.S. operations from 1999 to 2004, and President of the women’s health franchise from 1997 to 1999. Mr. Santini currently serves on the board of directors of Horizon Pharma, Inc., AMAG Pharmaceuticals Inc. and Sorin S.p.A., a global public medical device company, as well as a number of private companies. He also served on the Board of Directors for United Way and the Executive Committee and Board of Directors of the Indianapolis Chamber of Commerce. He holds an undergraduate degree in mechanical engineering from the University of Bologna and an M.B.A. from the Simon School of Business, University of Rochester. Mr. Santini’s long career at Eli Lilly and extensive domestic and international commercial, corporate strategy, business development and transaction experience make him an ideal fit for our board of directors.